Stock performance of Asian companies with oncology drugs presented at ASCO2023

Eisai leads in Tokyo (+3.16%), NKMax in Korea (+0.67%), Antengene in Hong Kong (+7.10%), Zelgen in Shanghai (+1.93%)

NEW YORK, NEW YORK, UNITED STATES, June 5, 2023/– The stock performance of select Asian companies with clinical data presented at the annual meeting of the American Society of Clinical Oncologists (ASCO) occurring over the weekend and until tomorrow has been summarized by OBiS, a biopharma analytics company specializing in new innovative business development tools and applications. Changes in stock price were based on today’s Asian market closing prices as compared to the market close prices on Friday, June 2nd 2023.

Japanese Stocks Evaluated: ASKA Pharma (4886.T); Astellas (4503.T); Daiichi (4568.T); Eisai (4523.T); Kyowa Kirin (4151.T); Oncolys BioPharma (4588.T); Ono Pharma (4528.T); Otsuka Holdings (4578.T); Sumitomo Pharma (4506.T); Takara Bio (4974.T); Takeda (4502.T).

The market cap weighted average stock price of the above eleven Japanese companies increased 1.8% versus the Nikkei gain of 2.2% over the same period (June 2nd to June 5th, 2023). Of these companies, Eisai experienced the highest 3.16% increase. Most of Eisai’s ASCO abstracts presented pertained to their two approved products Lenvima^® (lenvatinib), a VEGFR2 inhibitor, and Halaven^® (eribulin), a tubulin targeted mitotic spindle assembly inhibitor. Additionally, data on Eisai’s two new antibody-drug conjugates (ADCs) farletuzumab ecteribulin (MORAb-202) and MORAb-109 in preclinical rare gynecologic cancers was presented (ASCO abstract e17634). Early phase data on Eisai’s E7386 drug, a CREB-binding protein (CBP) /β-catenin inhibitor being tested in combination with lenvatinib, indicates that it is well tolerated in advanced hepatocellular carcinoma patients (ASCO abstract 4075, NCT04008797).

Korean Stocks Evaluated: AbClon (174900.KQ); Boryung (003850.KS); Eutilex (263050.KQ); Genexine (095700.KQ); LG Chem (051910.KS); NeoImmuneTech (950220.KQ); NKMax (182400.KQ) ; Oscotec Inc. (039200.KQ); STCube (052020.KQ). The market cap weighted average stock price of all nine Korean companies increased 0.2% versus the KOSPI index gain of 0.54% over the same period (June 2nd to June 5th, 2023). NKMax (NKGen Biotech) experienced the highest 0.67% increase. ASCO abstract 9057 presented preclinical and early phase clinical results demonstrating the anti-tumor effects associated with NKGen’s SNK01 autologous natural killer cells in combination with chemotherapy in NSCLC.

Chinese Stocks Evaluated (Hong Kong exchange): Abbisko (2256.HK); Akeso Pharma (9926.HK); Alphamab (9966.HK); Antengene (6996.HK); Ascentage (6855.HK); BeiGene (6160.HK); Carsgen (2171.HK); CSPC Pharma (1093.HK); CStone Pharma (2616.HK); Fosun Pharma (2196.HK); Genor Biopharma (6998.HK); Hansoh Pharma (3692.HK); Henlius (2696.HK); Innovent (1801.HK); Junshi Bio (1877.HK); Lepu Biopharm (2157.HK); Sihuan Pharmaceutical Holdings Group (0460.HK); Transcenta (6628.HK). The market cap weighted average stock price of all eighteen Hong Kong exchange traded Chinese companies experienced a decrease with a -0.84% change versus the Hang Seng index gain of +0.54% over the same period (June 2nd to June 5th, 2023). Antengene experienced the highest 7.10% increase. ASCO abstract 2526 presented early phase clinical data demonstrating the favorable results of Antengene’s TORC1/2 inhibitor onatasertib in advanced solid tumors.

Chinese Stocks Evaluated (Shanghai/Szechuan exchanges): Allist Pharma (688578.SS); Betta Pharma (300558.SZ); Chipscreen (688321.SS); Easton Biopharma (688513.SS); Hengrui (600276.SS); InventisBio (688382.SS); Jiangsu Yahong Meditech (688176.SS); Konruns (603590.SS); Shouyao Holdings (688197.SS); Sichuan Biokin (688506.SS); Zelgen (688266.SS). The market cap weighted average stock price of all eleven Shanghai/Szechuan exchange traded Chinese companies experienced a 0.47% increase versus the SSE composite index gain of +0.07% over the same period (June 2nd to June 5th, 2023). Zelgen experienced the highest 1.93% increase. Zelgen presented several abstracts on their clinical compounds jaktinib (JAK1/2/3 inhibitor), donafenib (a multi-targeted RTK inhibitor), and first-in-human results of ZG005, a dual specific checkpoint inhibitor targeting PD-1 and TIGIT (ASCO abstract e14504).

Other Asia (Australia, India, Taiwan) Stocks Evaluated: PharmaEssentia (6446.TWO); Sun Pharma (SUNPHARMA.NS); TaiRx (6580.TWO); Telix Pharma (TLX.AX) with gains of +0.43%, +0.92%, +0.61% and +1.57%, respectively.

OBiS has developed an Excel-based analytics tool based on the abstracts presented at ASCO. The tool integrates relevant clinical data, drug mechanism of action, target and key reference information as well as financial performance of the associated drug companies. The tool is available free of charge to select pharmaceutical and biotechnology companies actively developing cancer medication as well as to practicing oncologists.

About OBiS

OBiS is a privately owned New York City based healthcare analytics corporation offering a variety of products and services in business development, forecasting, new product planning, key opinion leader identification, market research, clinical trial, recruitment analytics and custom data services. OBiS serves primarily biotechnology and large pharmaceutical companies. OBiS was founded in 2002 by Rick Beasley, former Director of Oncology Market Research for Bristol-Myers Squibb. In 2020, OBiS opened a subsidiary office in Oloron-Sainte-Marie, France as a simplified joint-stock company (SAS) entity.

As part of its mission to explore new opportunities in drug development, OBiS has launched several exploratory projects covering personalized medicine (pharmacogenomics), French-Africa clinical development and French biotechnology facilitated growth programs. Additionally, a new program, termed the Artisan Brain Initiative is planned later this year to address the growing opportunities as well as concerns of advances in Artificial Intelligence (“The Brain Initiative” is a registered trademark of the US National Institute of Health).

OBiS Inc
12 West 32nd Street, 5th Floor
New York, NY 10001, United States

OBiS SAS
14 rue Despourrins
64400 Oloron-Sainte-Marie, France

DISCLAIMER
The information contained in this press release is being presented to advertise OBiS analytical services and as it is not intended to provide any financial investment or medical advice.